Cargando…
The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line
BACKGROUND: An in vitro model was developed to understand if celecoxib could synergize with Mitomycin C (MMC), commonly used for the prevention of non-muscle invasive bladder cancer recurrence, and eventually elucidate if the mechanism of interaction involves multi drug resistance (MDR) transporters...
Autores principales: | Pagliarulo, Vincenzo, Ancona, Patrizia, Niso, Mauro, Colabufo, Nicola Antonio, Contino, Marialessandra, Cormio, Luigi, Azzariti, Amalia, Pagliarulo, Arcangelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669624/ https://www.ncbi.nlm.nih.gov/pubmed/23705854 http://dx.doi.org/10.1186/1476-4598-12-47 |
Ejemplares similares
-
Small and Innovative Molecules as New Strategy to Revert MDR
por: Zinzi, Laura, et al.
Publicado: (2014) -
PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti–SARS-CoV-2 Activity: A Review About Its Pharmacological Properties and Structure Affinity Relationships
por: Abate, Carmen, et al.
Publicado: (2020) -
miRNAs for the Detection of MultiDrug Resistance: Overview and Perspectives
por: Gisel, Andreas, et al.
Publicado: (2014) -
Why PB28 Could Be a Covid 2019 Game Changer?
por: Colabufo, Nicola Antonio, et al.
Publicado: (2020) -
ABC transporters in CSCs membranes as a novel target for treating tumor relapse
por: Zinzi, Laura, et al.
Publicado: (2014)